Pancreatic Cancer Research

ResearcherVeterans Health AdministrationActive in the last 2 years

William Adrian Hall

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7017-6755; OpenAlex author ID A5006174923, A5015742706, A5112555632, A5114162264, A5130074051. Sources: ClinicalTrials.gov.

Their work

Papers
59 (first author 7, last author 8)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
149
Papers, trials and grants by year

2013: 3 papers · 2014: 4 papers · 2015: none · 2016: none · 2017: 6 papers · 2018: 4 papers, 1 trial · 2019: 6 papers · 2020: 8 papers · 2021: 8 papers · 2022: none · 2023: 6 papers · 2024: 6 papers · 2025: 5 papers · 2026: 3 papers

Papers 50 of 59

  1. AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.0291↗
  2. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  3. The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection. First author DOI 10.3390/cancers18203376↗
  4. Local Disease Control in Patients With Pancreatic Cancer. Last author DOI 10.1001/jamaoncol.2025.0156↗
  5. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  6. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Last author DOI 10.1016/j.ijrobp.2024.10.026↗
  7. Quality of Life and Toxicity in Patients With Pancreatic Ductal Adenocarcinoma Treated With Online Adaptive Stereotactic Magnetic Resonance Guided Radiation Th… Last author DOI 10.1016/j.ijrobp.2025.03.046↗
  8. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Last author DOI 10.1016/j.prro.2024.07.001↗
  9. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Last author DOI 10.1002/cam4.6582↗
  10. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Co-author DOI 10.1016/j.prro.2024.06.004↗
  11. The Use of MR-Guided Radiation Therapy for Pancreatic Cancer. Last author DOI 10.1016/j.semradonc.2023.10.002↗
  12. Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial. Last author DOI 10.1016/s2468-1253(24)00130-4↗
  13. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  14. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗
  15. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Co-author DOI 10.1001/jamaoncol.2022.6138↗
  16. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Co-author DOI 10.1002/jso.27265↗
  17. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Co-author DOI 10.1016/j.adro.2022.101122↗
  18. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  19. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Res… Last author DOI 10.1245/s10434-022-12742-3↗
  20. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  21. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Co-author DOI 10.1007/s10555-021-09993-z↗
  22. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Co-author DOI 10.1016/j.amjsurg.2020.12.001↗
  23. The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? Co-author DOI 10.1016/j.ctro.2021.04.002↗
  24. Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.soc.2021.06.009↗
  25. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.06.038↗
  26. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  27. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09149-3↗
  28. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  29. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? Co-author DOI 10.1007/s11605-019-04423-6↗
  30. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.03.022↗
  31. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Co-author DOI 10.1016/j.prro.2020.01.012↗
  32. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  33. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
  34. Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI bas… Co-author DOI 10.1371/journal.pone.0236570↗
  35. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. First author DOI 10.3389/fonc.2020.00460↗
  36. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  37. A preferred patient decubitus positioning for magnetic resonance image guided online adaptive radiation therapy of pancreatic cancer. Co-author DOI 10.1016/j.phro.2019.11.001↗
  38. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2019.06.016↗
  39. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  40. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. Co-author DOI 10.1038/s41698-019-0096-z↗
  41. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Co-author DOI 10.1186/s13014-019-1277-1↗
  42. Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-… First author DOI 10.3389/fonc.2019.01464↗
  43. The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. First author DOI 10.1007/s00261-017-1373-3↗
  44. Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2018.01.018↗
  45. PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study. Co-author DOI 10.1016/j.tranon.2018.06.011↗
  46. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002957↗
  47. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radia… Co-author DOI 10.1002/cncr.30706↗
  48. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
  49. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. First author DOI 10.1016/j.prro.2016.10.006↗
  50. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? First author DOI 10.1016/j.prro.2017.06.013↗

Trials 1

  1. Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Panc… Principal investigator NCT03704662↗

Closest collaborators

The 25 strongest of 149 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas B. Evans · 27 shared papers, 2017–2026 · strength 4.15
  2. Bradley A. Erickson · 32 shared papers, 2017–2025 · strength 4.07
  3. Susan Tsai · 27 shared papers, 2017–2026 · strength 3.64
  4. Kathleen K. Christians · 22 shared papers, 2017–2026 · strength 2.86
  5. Mandana Kamgar · 16 shared papers, 2020–2026 · strength 2.80
  6. Ben George · 19 shared papers, 2017–2024 · strength 2.17
  7. Mohammed Aldakkak · 16 shared papers, 2017–2026 · strength 2.14
  8. Callisia Nathelee Clarke · 14 shared papers, 2017–2026 · strength 1.91
  9. Beth E. Erickson · 9 shared papers, 2019–2026 · strength 1.43
  10. Kulwinder S. Dua · 8 shared papers, 2018–2025 · strength 1.00
  11. Sam Z. Thalji · 5 shared papers, 2023–2026 · strength 0.91
  12. Karyn A. Goodman · 6 shared papers, 2019–2025 · strength 0.91
  13. Thomas B. McFall · 4 shared papers, 2024–2026 · strength 0.89
  14. Paul S. Ritch · 10 shared papers, 2017–2020 · strength 0.87
  15. E.S. Paulson · 7 shared papers, 2017–2025 · strength 0.84
  16. Christopher H. Crane · 6 shared papers, 2017–2024 · strength 0.78
  17. X. Allen Li · 7 shared papers, 2017–2020 · strength 0.66
  18. Lois A. Daamen · 3 shared papers, 2021–2025 · strength 0.66
  19. Ashley N. Krepline · 6 shared papers, 2017–2021 · strength 0.61
  20. Naveen M. Kulkarni · 5 shared papers, 2020–2023 · strength 0.60
  21. Ben George · 3 shared papers, 2024–2026 · strength 0.59
  22. Joseph M. Herman · 5 shared papers, 2018–2025 · strength 0.58
  23. Parag Jitendra Parikh · 3 shared papers, 2021–2024 · strength 0.57
  24. Yongwoo David Seo · 2 shared papers, 2026 · strength 0.56
  25. Jasmijn Maria Westerhoff · 2 shared papers, 2024–2025 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.